%0 Journal Article %T Immune subgroups and the tumor microenvironment as a potential new biomarker to assess response to immunotherapy %A Kothari, Shawn %A Vokes, Everett E. %J Chinese Clinical Oncology %D 2019 %B 2019 %9 %! Immune subgroups and the tumor microenvironment as a potential new biomarker to assess response to immunotherapy %K %X Immunotherapy has emerged as a new standard of care therapeutic option for patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma. Following the recent presentation of Keynote-048, the use of Pembrolizumab either as a single agent or in combination with chemotherapy can be considered as first-line treatment for patients with measurable PD-L1 in their tumor or microenvironment (1). %U https://cco.amegroups.org/article/view/28769 %P S24 %@ 2304-3873